The major’s radioligand therapy has succeeded in an earlier line of prostate cancer therapy that presents a large market opportunity, but some observers are keen to see full data before raising their sales projections.
Novartis AG’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has met the primary endpoint in a pivotal second-line prostate cancer trial, sparking plans for a US filing that could significantly boost market opportunity, but some experts are awaiting full data before raising sales projections.
The Phase III PSMAfore trial set the radioligand therapy against standard-of-care androgen-receptor pathway inhibitor (ARPI) therapy in 469 people with...
Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.
Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.
MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.
The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.
More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
